

ABBRUPT



Atrial fibrillation

Atrial fibrillation is a condition that causes an irregular and often fast heartbeat.

New-onset atrial fibrillation

NOAF is defined as AF lasting for longer than 30 minutes in a patient without a known history of AF.

Best Treatment?

The best treatment for patients with NOAF whilst in ICU is uncertain.

Standard Care

Patients with NOAF are normally given amiodarone or beta-blockers but we do not know which treatment (if any) is best.

Previous Research

There are no prospective randomised studies comparing amiodarone with beta blockade reporting long term, clinically relevant outcomes.

ABBRUPT is a comparison of amiodarone and beta blockade to establish which management of AF is best to achieve optimal outcomes.

Improving Care

Clinical trials are part of everyday healthcare in the NHS and help us to work out which treatments work and which do not.

Patient & Public Consultation

has helped and advised us on many aspects of the trial design.

ABBRUPT Trial

It is essential that we find which intervention is better at treating New Onset Atrial Fibrillation.

The National Institute for Health Research (NIHR), Health and Technology Assessment Programme is funding this large clinical trial to answer this question and this means that your friend or relative may have taken part in the ABBRUPT Trial.

For further information, please speak to a member of the ICU team.